Value of topoisomerase II α, mib-1, p53, e-cadherin, retinoblastoma gene protein product, and her-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms

Applied Immunohistochemistry and Molecular Morphology

Volumn 9, Issue 3, 2001, Pages 215-221

  Gupta, D ^a   Shidham, V ^a   Holden, J ^a   Layfield, L ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Adrenal neoplasms; MIB 1; p53; Topoisomerase

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); GENE PRODUCT; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; UVOMORULIN;

ADRENAL CORTEX TUMOR; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS RATE; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; STAINING; TUMOR NECROSIS; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADRENAL CORTEX NEOPLASMS; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; CADHERINS; CELL DIVISION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NUCLEAR PROTEINS; RECEPTOR, ERBB-2; RETINOBLASTOMA PROTEIN; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034855810     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200109000-00004     Document Type: Article

References (34)

1. Adrenal cortical carcinoma. Clinicopathologic study of 34 cases
2. Adrenal cortical carcinoma: A clinical and pathologic study of 49 cases
3. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data
4. Pathologic features of prognostic significance in adrenocortical carcinoma
5. Adrenal cortical carcinoma: Flow cytometric study of 22 cases, an ECOG study
6. Expression of p53 in adrenocortical tumors: Clinicopathological correlations
7. P53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies
8. Bilateral adrenocortical carcinoma showing loss of heterozygosity at the p53 and RB gene loci
9. p53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies
10. Adrenocortical neoplasms: Role of prognostic markers MIB-1, P53, and RB
11. Mutations of the p53 gene in human functional adrenal neoplasms
12. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas
13. Human deoxyribonucleic acid topoisomerases: Molecular targets of anticancer drugs
14. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: A possible marker of differentiation between adenomas and carcinomas
15. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: Correlation with DNA topoisomerase II-alpha and p53 expression
16. Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer
17. Morphologic characteristics of benign and malignant adrenocortical tumors
18. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
19. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection
20. Adrenal cortical neoplasms. A study of 56 cases
21. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon
22. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms
23. The p53 tumor suppresser gene
24. P53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry
25. The role of pRb2/p130 protein in diagnosing lung carcinoma on fine needle aspiration biopsies
26. Allelic loss on chromosome 13q in human prostate carcinoma
27. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas
28. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ
29. Reduced E-cadherin expression correlates with unfavorable prognosis in adenoid cystic carcinoma of salivary glands of the oral cavity
30. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome
31. Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer
32. Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival
33. Studies of the Her 2/neu protooncogene in human breast and ovarian cancer